CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Premiums earned, net (Net of ceded premiums of $116 and $120 for the three months ended September 30, 2022 and 2021, respectively; net of ceded premiums of $354 and $370 for the nine months ended September 30, 2022 and 2021, respectively)		$ 267,892	$ 203,657	$ 814,566	$ 598,390
Non-Insurance revenue		585,311	222,647	1,757,579	439,020
Other income		3,614	859	5,751	2,550
Total revenues		856,817	427,163	2,577,896	1,039,960
Operating expenses:
Net medical claims incurred		839,799	436,325	2,560,307	1,109,248
Salaries and benefits		70,142	73,364	209,724	201,555
General and administrative expenses		47,832	45,846	152,569	130,110
Premium deficiency reserve (benefit) expense		(27,657)	20,761	(82,971)	48,661
Depreciation and amortization		616	120	2,028	398
Other expense		0	0	0	191
Total operating expenses		930,732	576,416	2,841,657	1,490,163
Loss from operations		(73,915)	(149,253)	(263,761)	(450,203)
Change in fair value of warrants payable		0	(115,152)	0	(66,146)
Interest expense		404	404	1,197	2,790
Amortization of notes and securities discounts		9	22	27	13,708
Loss (gain) on investment		(980)	0	10,187	0
Net loss		$ (75,308)	$ (34,527)	$ (254,798)	$ (400,555)
Per share data:
Net loss per share attributable to Class A and Class B common stockholders - basic (in dollars per share)	[1]	$ (0.16)	$ (0.08)	$ (0.54)	$ (0.98)
Net loss per share attributable to Class A and Class B common stockholders - diluted (in dollars per share)	[1]	$ (0.16)	$ (0.08)	$ (0.54)	$ (0.98)
Weighted average number of common shares outstanding
Basic weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	[1]	477,690,204	414,572,706	475,609,571	410,417,493
Diluted weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	[1]	477,690,204	414,572,706	475,609,571	410,417,493
Net unrealized loss on available-for-sale investments		$ (2,407)	$ (197)	$ (8,826)	$ (620)
Comprehensive loss		$ (77,715)	$ (34,724)	$ (263,624)	$ (401,175)

[1] Because the Company had a net loss during the three and nine months ended September 30, 2022 and 2021, the Company's potentially dilutive securities, which include stock options, restricted stock, preferred stock, and warrants to purchase shares of common stock and preferred stock, have been excluded from the computation of diluted net loss per share, as the effect would be anti-dilutive.